Clinical trials have recently begun on a chimeric IgG1 anti-CD105 monoclonal antibody (TRC105) that binds human endoglin with high avidity, indicating that CD105 might be a promising anti-angiogenic target of cancer therapy [10]. This evidence concerns the gene ENG and cancer.